fitness news
,
Font size Women’s Health
Australian Diabetes Society publishes new guidance on insulin glargine
– Reported,16 November, 2012 Pharmacy News
Sanofi has today welcomed the Australian Diabetes Society (ADS) decision to update their advice regarding the safety of Lantus.
In a position statement published on the ADS website on 17 October 2012, the ADS reported in light of new data.
ADS believes that the current data do not support a relationship between the use of insulin glargine and malignancy. Patients with diabetes taking insulin glargine (Lantus) do not need to change their insulin therapy. Patients with diabetes can be initiated on glargine therapy without concern that insulin glargine will increase the risk of developing a malignancy.
Commenting on this updated position, Associate Professor Michael dEmden, Vice President of the ADS, said The recent data reiterates to prescribers that insulin glargine does not increase the incidence of cancer, and specifically there is no increase in breast cancer rates.
Dr Tal Rapke, Sanofi Acting Medical Director, said Sanofi welcomes this updated statement which helps bring clarity to patients and doctors on the appropriateness of insulin glargine as a treatment for patients with diabetes.
The announcement from the ADS comes on the back of the results of a large-scale epidemiological program, conducted by independent researchers in the northern European countries, at Kaiser Permanente in Northern and Southern California, and at the University of North Carolina in the United States, providing further evidence that there was no increased risk of cancer in people with diabetes treated with Lantus compared to those treated with other insulins.
For more Australia News Click Here
